Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.33 |
| ▸ | PPARG | P37231 | 6/20 | 0.33 |
| ▸ | PPARD | Q03181 | 6/20 | 0.33 |
| ▸ | PPARA | Q07869 | 6/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12196374 | 1.00 | CYP4F2 (0.40) | CYP4F2CYP4A11AKR1B1GPR84PPARG | |
| SCHEMBL2844700 | 1.00 | CYP4F2 (0.40) | CYP4F2CYP4A11AKR1B1GPR84PPARG | |
| SCHEMBL608116 | 0.92 | CYP4F2 (0.42) | CYP4F2CYP4A11GPR84PPARGPPARD | |
| SCHEMBL28956794 | 0.92 | CYP4F2 (0.42) | CYP4F2CYP4A11GPR84PPARGPPARD | |
| SCHEMBL350668 | 0.91 | AKR1B1 (0.37) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL6756944 | 0.91 | AKR1B1 (0.37) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL28125208 | 0.89 | CYP4F2 (0.39) | CYP4F2CYP4A11AKR1B1GPR84PPARG | |
| SCHEMBL120634 | 0.89 | CYP4F2 (0.39) | CYP4F2CYP4A11AKR1B1GPR84PPARG | |
| SCHEMBL392507 | 0.89 | CYP4F2 (0.39) | CYP4F2CYP4A11AKR1B1GPR84PPARG | |
| Ethylene Glycol SCHEMBL500121 | 0.87 | CYP4F2 (0.44) | CYP4F2CYP4A11AKR1B1GPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3487835-B1 | METHOD FOR THE RESOLUTION OF BACLOFEN SALTS | UNIV ROUEN (FR) | 2020-04-08 | — | — | EP | disclosed |
| EP-2282991-B1 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2018-01-24 | — | — | EP | disclosed |
| US-8461312-B2 | Method for the production of 1,4-benzothiepin-1,1-dioxide derivatives | SANOFI (FR) | 2013-06-11 | — | — | US | disclosed |
| US-8461312-B2 | Method for the production of 1,4-benzothiepin-1,1-dioxide derivatives | SANOFI (FR) | 2013-06-11 | — | — | US | disclosed |
| US-8461312-B2 | Method for the production of 1,4-benzothiepin-1,1-dioxide derivatives | SANOFI (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20110245486-A1 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245486-A1 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245486-A1 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-10-06 | — | — | US | disclosed |
| EP-2282991-A2 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | Sanofi-Aventis Deutschland GmbH (DE) | 2011-02-16 | — | — | EP | disclosed |
| US-20100160670-A1 | NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL-2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID | AVENTIS PHARMA S.A. (FR) | 2010-06-24 | — | — | US | disclosed |
| EP-0599883-B1 | CONTINUOUS PROCESS FOR THE PREPARATION OF 2-ETHYL-2-(HYDROXYMETHYL)HEXANAL AND 2-BUTYL-2-ETHYL-1,3-PROPANEDIOL | EASTMAN CHEM CO (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1996016051-A1 | HYPOLIPIDEMIC BENZOTHIAZEPINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
| EP-0599883-A1 | CONTINUOUS PROCESS FOR THE PREPARATION OF 2-ETHYL-2-(HYDROXYMETHYL)HEXANAL AND 2-BUTYL-2-ETHYL-1,3-PROPANEDIOL. | EASTMAN KODAK CO (US) | 1994-06-08 | — | — | EP | disclosed |
| US-5235118-A | Reacting 2-ethylhexanal with formaldehyde in presence of tertiary amine catalyst | EASTMAN KODAK COMPANY (US) | 1993-08-10 | — | — | US | disclosed |
| WO-1993002035-A1 | CONTINUOUS PROCESS FOR THE PREPARATION OF 2-ETHYL-2-(HYDROXYMETHYL)HEXANAL AND 2-BUTYL-2-ETHYL-1,3-PROPANEDIOL | EASTMAN KODAK COMPANY (US) | 1993-02-04 | — | — | WO | disclosed |
| US-5177267-A | Distillation | EASTMAN KODAK COMPANY (US) | 1993-01-05 | — | — | US | disclosed |
| US-5146004-A | Reaction of ethyl hexanal, aqueous formaldehyde in presence of tertiapy amine, hydrogenation | EASTMAN KODAK COMPANY (US) | 1992-09-08 | — | — | US | disclosed |
| EP-0183150-B1 | PROCESS FOR THE PREPARATION OF MODIFIED POLYISOCYANATES AND THEIRUSE IN THE PREPARATION OF POLYURETHANE COATINGS | BAYER AG (DE) | 1990-04-18 | — | — | EP | disclosed |
| US-4656223-A | Process for the production of modified polyisocyanates, the compounds obtainable by this process and their use in polyurethane lacquers | BAYER AKTIENGESELLSCHAFT (DE) | 1987-04-07 | — | — | US | disclosed |
| EP-0183150-A2 | Process for the preparation of modified polyisocyanates and theiruse in the preparation of polyurethane coatings | BAYER AG (DE) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245486-A1 | METHOD FOR THE PRODUCTION OF 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES | BBOX1, SULT1E1, PTGS1 | CYP4F2 202/4885CYP4A11 47/4885AKR1B1 1726/4885 |
| US-20100160670-A1 | NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL-2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID | HCAR2, HCAR3, HCAR1 | CYP4F2 164/4885CYP4A11 39/4885AKR1B1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.